Abstract: A non-naturally occurring microbial organism includes a microbial organism having a reductive TCA or Wood-Ljungdahl pathway in which at least one exogenous nucleic acid encoding these pathway enzymes is expressed in a sufficient amount to enhance carbon flux through acetyl-CoA. A method for enhancing carbon flux through acetyl-CoA includes culturing theses non-naturally occurring microbial organisms under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block. Another non-naturally occurring microbial organism includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock.
Type:
Grant
Filed:
January 21, 2011
Date of Patent:
November 1, 2011
Assignee:
Genomatica, Inc.
Inventors:
Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya
Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 31, 2010
Date of Patent:
October 4, 2011
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: Specially modified microbial growth surfaces improve bacterial recovery or counts when testing for the presence or absence of microbial cells or performing microbial enumerations.
Type:
Grant
Filed:
November 10, 2008
Date of Patent:
September 27, 2011
Assignee:
The Regents of the University of California
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 30, 2010
Date of Patent:
September 20, 2011
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 31, 2010
Date of Patent:
September 20, 2011
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 30, 2010
Date of Patent:
September 20, 2011
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: The invention is directed to isolated genomic polynucleotide fragments that encode human resistin and human syntaxin binding protein 2, vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human resistin and human syntaxin binding protein 2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Abstract: A simple method for measuring allergens is disclosed, by which the amount of environmental allergens can be measured simply without using an anti-allergen antibody. In the method for measuring an environmental biological allergen(s), a solution containing a substrate of a protease which the allergen(s) has (have) is brought into contact with a test sample collected by using an adhesive sheet, which substrate gives a visible color change as a result of an enzyme reaction; and measuring the protease activity in the test sample using the color change of the substrate solution as an index, thereby measuring the biological allergen(s).
Abstract: Methods for making a modified Cry3A toxin are disclosed. Such methods include the insertion of a protease recognition site that is recognized by a gut protease of a target insect, such as corn rootworm, into at least one position of a Cry3A toxin so that a modified Cry3A toxin is thus designed. The coding sequence of the modified Cry3A toxin may be transformed into a host cell and the host cell grown under conditions that allow the host cell to produce the modified Cry3A toxin. The host cell may be a plant cell and the plant may be comprised in a transgenic plant. Thus, the transgenic plant may be used to produce the modified Cry3A toxin.
Abstract: The present invention relates to methods for producing variants of a parent JP170 subtilase and of a parent BPN? subtilase and to JP170 and BPN? variants having altered properties as compared to the parent JP170/BPN? subtilase.
Abstract: The present invention is to construct a DNA replication reaction system which is excellent in versatility and is easily used. An amino acid sequence of a PCNA monomer which is one of factors involved in DNA replication is prepared so that amino acid residues causing mutual charge repulsion constitute a site which causes, when an N terminal region of the PCNA monomer and a C terminal region of another PCNA monomer act as an interface to form a multimeric complex, an intermolecular interaction of the monomers in an interface region of the monomers.
Abstract: The invention relates to ?-galactoside binding protein (?GBP) and compositions, including pharmaceutical compositions, comprising ?GBP for use in therapy and related applications. In particular, the invention relates to use of ?GBP and the manufacture of medicaments for the treatment or prevention of conditions in which disease associated cell division occurs, wherein the cells which result from said disease associated cell division comprise a cell in respect of which the effect of ?GBP is not inhibition of growth. The invention also relates to methods of inducing apoptosis, methods of treating or preventing conditions in which disease associated cell division occurs and methods of assessing the suitability of ?GBP as a therapeutic agent.
Abstract: A TNF-? binding polypeptide is provided, which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, expression vector comprising the nucleic acid, and host cell comprising the expression vector are also provided. Also provided are methods comprising a step of affinity separation or detection, in which step a polypeptide according to the invention is used. Such methods may be used for reducing the content of TNF-? in a body fluid.
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 30, 2010
Date of Patent:
August 9, 2011
Assignee:
Affinergy, Inc.
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ??RACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
July 26, 2011
Assignee:
The Board of Trustees of the Leland Standford Junior University
Abstract: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect (“analyte module”). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.
Type:
Grant
Filed:
August 31, 2010
Date of Patent:
June 28, 2011
Assignee:
Affinergy, Inc.
Inventors:
Wayne F. Beyer, Jr., Robin Hyde-DeRuyscher, Paul T. Hamilton, Ray Edward Benson
Abstract: The present invention describes the identification, isolation and cloning of two human presenilin genes, PS-1 and PS-2, mutations in which lead to Familial Alzheimer's Disease. Also identified are presenilin homologue genes in mice, C. elegans and D. melanogaster. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the constructions of transgenic animals expressing the mutant genes.
Type:
Grant
Filed:
January 26, 1996
Date of Patent:
November 16, 1999
Assignees:
The Hospital for Sick Children, HSC Research and Development Limited Partnership, The Governing Council of the University of Toronto
Inventors:
Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
Abstract: An expression system for expressing gene products from recombinant Bordetella strains and specific nucleic acid molecules useful in transforming Bordetella strains for such expression are described. A nucleic acid molecule may comprise a Bordetella promoter operatively coupled to a heterologous gene encoding a non-Bordetella gene product with the heterologous gene transcriptionally regulated by the Bordetella promoter. The nucleic acid molecule may further comprise a further nucleic acid molecule encoding a leader sequence for secretion of the non-Bordetella gene product. Another nucleic acid molecule may comprise a Bordetella promoter coupled to a nucleic acid sequence encoding a non-Bordetella leader sequence for secretion of a gene product, which may be a Bordetella gene product or a non-Bordetella gene product.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
August 3, 1999
Assignee:
Connaught Laboratories Limited
Inventors:
Sheena M. Loosmore, Reza Khayyam Yacoob, Gavin Ross Zealey, Michel Henri Klein
Abstract: The present invention relates to a method for producing human myoglobin by inserting a DNA sequence comprising a human myoglobin gene into a tryptophan promoter-containing vector, followed by making E. coli with the thus-obtained expression vector express a holo-type human myoglobin. Using this method, it is possible to directly and efficiently produce a heme-structured, holo-type human myoglobin by gene recombination technology.